PASC Post Acute Sequelae of COVID 19
8
4
6
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
Brain Stimulation in Long COVID
Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2